Sort Through Meds for Managing Hemophilia
New meds Jivi (JIH-vee) and Rebinyn (reh-bee-NYNE) will raise questions about managing bleeding in hemophilia patients.
Jivi (recombinant PEGylated factor VIII) will be for hemophilia A. It will compete with other long-acting (Adynovate, Eloctate, etc) and short-acting (Kogenate FS, Recombinate, etc) factor VIII products.
Rebinyn (recombinant glycoPEGylated factor IX) is for the less common hemophilia B. It's an alternative to long-acting (Alprolix, Idelvion, etc) or short-acting (BeneFix, Ixinity, etc) factor IX products.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote